| Name | Title | Contact Details |
|---|
Unlike traditional approaches that only address symptoms, Cardionomic addresses the conditions root cause of reduced contractility. The therapy uses neuromodulation to benignly increase contractility, thus improving cardiac output therefore increasing renal flow and end organ perfusion. Benignly increasing contractility decreases negative hormonal signaling, and improves in-hospital morbidity/mortality. This breakthrough therapy is also expected to increase pharmacological tolerance at discharge, which will reduce costly readmission and extend life. Spun off from Denali Medical II, a New Enterprise Associates (NEA) backed incubator, Cardionomic is funded by NEA, Greatbatch Medical and Cleveland Clinic Foundation.
Wolters Kluwer Clinical Drug Information connects you to the information and technology you need to strengthen medication decision making.
Lyniate offers industry-leading interoperability solutions that deliver simple and seamless integration of all health data. With two Best-in-KLAS products, Lyniate Corepoint and Lyniate Rhapsody, we established a proven reputation on which we continue to build adaptable interoperability solutions that connect the healthcare ecosystem to unlock the full potential of data. We partner with providers, health plans, and health tech solutions around the world to enable rapid, reliable, and scalable interoperability, both vertically and horizontally, on-premises and in the cloud.
SNBL USA is a part of the SNBL Group of companies and is a subsidiary of Shin Nippon Biomedical Laboratories (SNBL). As part of the SNBL Group, SNBL USA shares the corporate mission statement: We are committed to freeing patients from suffering by
Advanced Patient Advocacy is a Richmond, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.